Anzeige
Mehr »
Donnerstag, 24.09.2026 - Börsentäglich über 12.000 News
Rekordumsätze, Humana-Deal und nur 28 Mio. CAD Börsenwert
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 859034 | ISIN: US1266501006 | Ticker-Symbol: CVS
Tradegate
24.09.26 | 15:38
74,88 Euro
-0,72 % -0,54
1-Jahres-Chart
CVS HEALTH CORPORATION Chart 1 Jahr
5-Tage-Chart
CVS HEALTH CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
75,3875,6016:09
74,8474,9415:39
ACCESS Newswire
126 Leser
Artikel bewerten:
(0)

CVS Health: Aetna Expands Bundled Oncology Prior Authorizations, Easing Provider Burden and Accelerating Member Access to Care

  • Oncology bundling to support all eligible Medicaid members for all cancer types
  • Full roll-out across all Aetna businesses in 2027

Originally published on CVS Health Company Newsroom

WOONSOCKET, RI / ACCESS Newswire / September 24, 2026 / Aetna, a CVS Health company (NYSE:CVS), is expanding prior authorization bundles across all cancer types for members in eligible1 Medicaid states as of September 1, with plans to expand across all lines of business in 2027. This expansion builds on the success of the initial roll-out, with almost 25% of eligible members receiving a bundled prior authorization, assuring their services have been approved in advance to accelerate their access to care.

On average, Aetna saw that providers were submitting four separate prior authorizations for each member in need of cancer treatments.2 By offering a single, secure prior authorization for a bundle of cancer treatments, Aetna is helping patients access care simply throughout their treatment journey. Prior authorization bundles combine medical oncology, including chemotherapy and immunotherapy where appropriate, and/or radiation oncology services with associated high-tech imaging needs, such as MRI or CT scans, into one request submitted through a single portal.

"A cancer diagnosis can be overwhelming for patients and families, and the care team should be focused on their patient, not paperwork," said Katerina Guerraz, Aetna Chief Operating Officer and President of Medicaid. "By approving a broader set of treatments and related services upfront, we're removing barriers that can delay care. Oncologists have the flexibility to make care decisions as treatment plans evolve, and individuals can focus on what matters most: their health, recovery, and time with their loved ones."

Administrative burden remains a significant challenge for healthcare providers. According to the latest Aetna Provider Survey, 74% of providers identified administrative burden as the top challenge facing clinical staff today, and nearly one-third (31%) cited prior authorization management as the single largest contributor.

By reducing this burden, Aetna can help clinicians unlock more time for patient care. In fact, 30% of Aetna Provider Survey respondents believed they could save more than an hour and 80% expect to save more than 30 minutes daily on administrative tasks through technology solutions such as bundles.

Aetna expects to expand eligibility to Medicare and Commercial members in the first half of 2027.

###

About Aetna

Aetna, a CVS Health business, serves an estimated 37 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, and medical management capabilities, Medicaid health care management services, workers' compensation administrative services and health information technology products and services. Aetna's customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care professionals, governmental units, government-sponsored plans, labor groups and expatriates. For more information, visit Aetna.com (e.g., clinical diagnoses, eligibility criteria, participation in a disease state management program).

About CVS Health

CVS Health is a leading health solutions company simplifying healthcare one person, one family and one community at a time. As of June 30, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated 37 million people through a broad range of health insurance products and related services. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Media contact

Phil Blando
202-258-4978
Phillip.Blando@CVSHealth.com

1Providers in OK, IL, MD, NJ, VA, FL, KY, WV that utilize the Eviti portal to submit prior authorizations.

2Aetna Data Sciences

Find more stories and multimedia from CVS Health at 3blmedia.com.

Contact Info:
Spokesperson: CVS Health
Website: https://www.3blmedia.com/profiles/cvs-health
Email: info@3blmedia.com

SOURCE: CVS Health



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aetna-expands-bundled-oncology-prior-authorizations-easing-provider-b-1226578

© 2026 ACCESS Newswire
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.